Sale or disposal

Ref: MHL/Sec&Legal/2026-27/41 August 20, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Board of Directors of Metropolis Quality Solutions Private Limited (“MQSPL”), a wholly owned subsidiary of Metropolis Healthcare Limited (“the Company”), has today approved the offer and issuance of Optionally Convertible Redeemable Preference Shares (“OCRPS”). Upon successful subscription to and subsequent conversion of these OCRPS into equity shares, MQSPL will cease to be a wholly owned subsidiary of the Company but will continue to remain a subsidiary of the Company. The details as required under the SEBI Listing Regulations are provided in ‘Annexure A’ with this intimation. You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head – Legal & Secretarial Encl: a/a Annexure A (Pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026) Particulars Details The amount and percentage of the turnover or Metropolis Quality Solutions Private Limited (‘MQSPL’) is a private limited company revenue or income and net worth contributed incorporated on September 15, 2025, under the Indian Companies Act, 2013. by such unit or division or undertaking or subsidiary or associate company of the listed MQSPL is yet to commence its business operations and hence has not contributed to the e ntity during the last financial year turnover, revenue, income, or net worth of the Company. Date on which the agreement for sale has been Not applicable entered into The expected date of completion of The conversion of Optionally Convertible Redeemable Preference Shares (“OCRPS”) sale/disposal into equity shares (at a ratio of 1:1) is subject to the fulfilment of the terms and conditions attached to the issuance and will be executed in tranches. The overall timeline for the complete conversion is expected to be up to 6 years. Consideration received from such sale/disposal Offer and issuance of 10,000 OCRPS of face value of INR 10/- (Indian Rupees Ten only) each, at par, aggregating to INR 1,00,000/- (Indian Rupees One Lakh only). Brief details of buyers and whether any of the Dr. Puneet Kumar Nigam, former Chief Quality Officer of the Company, is the proposed buyers belong to the promoter/ promoter allottee. He does not belong to the Promoter or Promoter Group of the Company. group/group companies. If yes, details thereof Whether the transaction would fall within The transaction does not qualify as a related party transaction. related party transactions? If yes, whether the same is done at “arm’s length” Whether the sale, lease or disposal of the Yes, the transaction is outside the scope of Scheme of Arrangement. undertaking is outside Scheme of Arrangement? If yes, details of the same The provisions of Regulation 37A of the SEBI Listing Regulations are not applicable for including compliance with regulation 37A of the proposed issuance. LODR Regulations Additionally, in case of a slump sale, indicative Not applicable disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.